Shoshana Lipson, a patient advocate and founder of the “CGRP & Migraine Community ” on Facebook explains the patient perspective of CGRP inhibitors.
Shoshana Lipson, a patient advocate and founder of the “CGRP & Migraine Community ” on Facebook explains the patient perspective of CGRP inhibitors.
Transcript:
Are patients knowledgeable about [calcitonin gene-related peptide] CGRP inhibitors?
So, I would say it is kind of a mixed bag in terms of knowledge about the CGRP medications. Some people are very knowledgeable; they knew that they were coming, they had it planned, I personally had my doctor’s appointment set around a week after the first medication was approved. I knew it was coming and I knew I wanted to try it.
But then you’ve got people on the other end of the spectrum who are still saying “What? What’s CGRP and what does that stand for, what does it do, does this actually potentially help someone who has migraine?” So, we have the full range of the spectrum, and then again, trying to take that information and put it into simple language is just really, really crucial. So, we not only have my support group, but there are obviously also posts in the other migraine groups, but I’m also writing articles and speaking at different places just to educate patients about these new medications and also what they’re like in real-world application.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More